Table 5.
Hazard ratio (95% CI)* | |||
---|---|---|---|
Cancer type | Stroke (n=214, 283) | Osteoarthritis (n=626,514) | Macular degeneration (n=365,430) |
Any cancer | 1.34 (1.32–1.36) | 1.31 (1.29–1.32) | 1.37 (1.36–1.39) |
Prostate | 1.08 (1.05–1.10) | 1.20 (1.18–1.21) | 1.16 (1.14–1.19) |
Lung | 1.68 (1.61–1.76) | 1.42 (1.38–1.46) | 1.48 (1.42–1.53) |
Colorectal | 1.21 (1.17–1.26) | 1.11 (1.08–1.14) | 1.23 (1.19–1.27) |
Bladder | 1.35 (1.29–1.41) | 1.24 (1.20–1.28) | 1.41 (1.37–1.46) |
Head and neck | 1.39 (1.32–1.47) | 1.18 (1.14–1.22) | 1.41 (1.35–1.47) |
Melanoma | 1.25 (1.18–1.33) | 1.30 (1.25–1.34) | 1.43 (1.37–1.49) |
Lymphoma | 1.18 (1.10–1.27) | 1.15 (1.10–1.20) | 1.17 (1.11–1.24) |
Renal | 1.40 (1.29–1.52) | 1.38 (1.31–1.45) | 1.44 (1.35–1.53) |
Adjusted for sex, number of clinic visits in year prior to baseline, follow-up time, cancer treatment, high cholesterol, hypertension, obesity, coronary arterial disease, diabetes, stroke, race and confidence interval with Bonferroni Correction. Statistically significant associations are marked in bold.